✓ Translated by DotMD AI Clinical Council Source: BMC medicine • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #42436536 ↗

Phase III Randomized Trial: Randomized, multicenter phase 3 study evaluating radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma patients achieving CR/PR after induction chemotherapy

Original Paper Title: “Randomized, multicenter phase 3 study evaluating radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma patients achieving CR/PR after induction chemotherapy”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • In NPC patients achieving CR/PR after induction chemotherapy, IC + RT demonstrated a favorable safety profile compared with IC+CCRT. Although the observed survival outcomes were numerically comparable, the premature termination of the trial and insufficient statistical power preclude a definitive noninferiority claim.
  • Study Design & Sample: Phase III Randomized Trial published in BMC medicine (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in BMC medicine (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: The present study sought to compare the clinical efficacy and safety profiles of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) patients who attained complete or partial response (CR/PR) following induction chemotherapy (IC). Key clinical takeaway: In NPC patients achieving CR/PR after induction chemotherapy, IC + RT demonstrated a favorable safety profile compared with IC+CCRT. Although the observed survival outcomes were numerically comparable, the premature termination of the trial and insufficient...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (BMC medicine, 2026-07-11; Phase III Randomized Trial; Rigor 82/100): In NPC patients achieving CR/PR after induction chemotherapy, IC + RT demonstrated a favorable safety profile compared with IC+CCRT. Although the observed survival outcomes were numerically comparable, the premature termination of the trial and insufficient statistical power preclude a definitive noninferiority claim.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: medullary-adenocarcinoma → Condition: lymphomatoid-granulomatosis →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42436536: Phase III Randomized Trial: Randomized, multicenter phase 3 study evaluating radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma patients achieving CR/PR after induction chemotherapy

3 of 3 Free Questions Remaining